Dextera Surgical Inc (NASDAQ:DXTR), which happens to be one of the trusted and renowned providers in the development as well as the commercialization of the MicroCutter 5/80™ stapler has today made the much awaited news. The company has announced its move to file a 510(k) with the U.S. Food and Drug Administration for expanded indications for use, which is indeed a progressive move.
As a matter of fact, the provider is looking to expand the indications for the MicroCutter to include liver, kidney, spleen surgery and pancreas. The president and CEO of Dextera Surgical Inc, Julian Nikolchev while addressing a press conference said, “These indications account for more than 80,000 procedures in the U.S., where the small size and increased articulation of the MicroCutter 5/80 may contribute to less invasive approaches to treat these patients. In Europe, where we have the CE Mark for these indications, surgeons are currently using the MicroCutter 5/80 successfully in these applications.”
At this particular point, the MicroCutter 30 and MicroCutter 5/80 Stapler will be found useful in the transection and resection in multiple open or minimally invasive urologic, pediatric surgical procedures, thoracic, as well as application for transection, creation of anastomoses in the small and large intestine, resection and the appendix transaction.
While speaking to a number of top news reporters, one of the top officials working with the company said that technological advancements which are sweeping across the globe in the current times as well as the major efforts that are being redirected into research are important towards making even greater advancements in the medical arena.
He added to say that in a world which was experiencing the emergency of new disease and ailments from time to time, it was critical to be well prepared to counter such conditions at any point in time. He expressed his excitement following the efforts he had already witnessed from top companies that were working around the clock to ensure that all was well with the world’s ailing population.
He concluded by saying that the company was looking up to an even better tomorrow that would see them develop top end solutions to patients globally and also at the same time be able to generate higher revenues.
Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.